Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
Swiss Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Iowa
Wake Forest University Health Sciences
Jonsson Comprehensive Cancer Center
UNICANCER
Hackensack Meridian Health
Intergroupe Francophone de Cancerologie Thoracique
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Second Affiliated Hospital of Nanchang University
Dana-Farber Cancer Institute
University of Utah
Abramson Cancer Center at Penn Medicine
Fundación GECP
Sun Yat-sen University
Intergroupe Francophone de Cancerologie Thoracique
Rutgers, The State University of New Jersey
Università Vita-Salute San Raffaele
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Fundación GECP
Fundación GECP
Intergroupe Francophone de Cancerologie Thoracique
Washington University School of Medicine
Weill Medical College of Cornell University
Duke University
NRG Oncology
University of Alabama at Birmingham
First Affiliated Hospital of Zhejiang University
University Hospital, Limoges
Shanghai Junshi Bioscience Co., Ltd.
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Samsung Medical Center
Stanford University
Fundación GECP
Fundación GECP
Fundación GECP
Fundación GECP
Fox Chase Cancer Center
Latin American Cooperative Oncology Group
Tufts Medical Center
Spanish Lung Cancer Group
Xiangya Hospital of Central South University